Taking simvastatin in the morning compared with in the evening: randomised controlled trial by Wallace A et al.
Taking simvastatin in the morning compared with in the
evening: randomised controlled trial
Alan Wallace, David Chinn, Greg Rubin
Statins are widely prescribed for the primary and
secondary prevention of coronary artery disease. They
act by inhibiting the enzyme HMG CoA reductase,
which controls synthesis of cholesterol in the liver.
Most manufacturers of statins recommend that they
are taken at night, on the basis of physiological studies
which show that most cholesterol is synthesised when
dietary intake is at its lowest.1 One small clinical trial
found that taking smaller doses of simvastatin than are
used in treatment, in the morning, was less efficient.2
However, a trial using atorvastatin found no significant
difference in cholesterol concentrations between
patients taking the statin in the morning and those
taking it in the evening.3
Doubt has been cast on whether statins need to be
taken at night,4 particularly as many patients also
receive treatment with other cardioprotective drugs
and compliance may be compromised by multiple
dosing.5 We determined whether taking simvastatin in
the morning had significantly different efficiency from
taking it in the evening, by measuring cholesterol
concentrations in fasting patients’ serum.
Participants, methods, and results
We randomised adults stable on 10 or 20 mg of simva-
statin at night for primary or secondary prevention of
coronary heart disease, stroke, or peripheral vascular
disease, to dosings in the morning or evening for a
period of eight weeks. We measured fasting blood lipid
profiles at baseline and at eight weeks. We sampled
blood between 8 30 and 9 30 am.Patients randomised to
dosing in the morning were told not to omit it on the
day of the follow up blood sample. The primary
outcomemeasure was change in fasting total cholesterol
concentration between baseline and follow up. We also
measured the concentration of high density lipoprotein,
alanine transaminase, low density lipoprotein, and
triglyceride. We checked compliance by counting the
number of tablets taken between the two visits.
We compared mean lipid concentrations between
treatment groups in an intention to treat analysis using
analysis of covariance with initial concentration as a
covariate. We compared proportions with 2 tests and
means with unmatched t tests. The 5% level indicated
statistical significance, and we analysed data in SPSS.
To show a significant 4% change in mean cholesterol
concentration with 80% power, assuming a mean coef-
ficient of variation of 5.5% among patients, we needed
60 patients.
A computer search identified 96 patients who took
simvastatin. We excluded 13 because they already took
simvastin in the morning. Of the 83 eligible patients,
60 (72%) accepted. We randomised the 27 men and 33
women of mean age 66 (range 44-82) to taking the
drug in the mornings or in the evenings. Thirty six
patients took 10 mg a day and 24 took 20 mg a day. Sex
and daily dose did not differ between groups (P > 0.6).
A total of 57 patients completed the trial; one withdrew
and two defaulted. In the intention to treat analysis, we
assumed that the lipid profiles of these patients did not
change between baseline and follow up. Change in
blood lipids was normally distributed and switching
taking simvastatin from in the evening to in the morn-
ing resulted in statistically significant increases in total
and low density lipoprotein cholesterol (table).
Compliance did not differ between the groups (mean
number of tablets 1, standard deviation 5 for both
groups; P = 0.9).
Comment
Simvastatin is probably best taken at night because
concentrations of total cholesterol and of low density
lipoprotein are significantly greater when it is taken in
the morning. Simvastatin is the most widely
prescribed statin in the United Kingdom, and this
finding has implications for compliance in preventing
coronary heart disease. The absence of a similar effect
with atorvastatin may be explained by its longer elimi-
nation half life.
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Lipid concentrations at baseline (mean and standard deviation) with mean and 95%
confidence interval of the difference in the change after eight weeks of morning versus
evening dosing (n=60)
Lipid
Mean concentration
P value*Baseline (SD) Change (95% CI)
Total cholesterol (mmol/l) 4.4 (0.8) 0.38 (0.17 to 0.59) 0.001
Low density lipoprotein (mmol/l) 2.4 (0.6) 0.25 (0.06 to 0.44) 0.012
High density lipoprotein (mmol/l) 1.3 (0.3) 0.02 (−0.03 to 0.08) 0.43
Triglyceride (mmol/l) 1.6 (0.8) 0.09 (−0.31 to 0.48) 0.67
Alanine transaminase (IU/l) 22.0 (11.0) −1.32 (−5.6 to 3.0) 0.55
*Analysis of covariance with adjustment for initial concentration.
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